Share this

Over 40 guests were invited to take part in tours of the three-storey laboratory facility at Charnwood Campus which will house over 150 scientists.

With the recent acquisition of Aurelia Bioscience, they are now well prepared for the next exciting phase of their development focused on drug discovery and innovation.

The company is able to provide a fully integrated drug discovery solution to its clients, with teams across all disciplines working in the space. Bringing their new market leading laboratories online has quadrupled their capacity.

Project-proven capabilities include bioscience, computational chemistry, medicinal chemistry and process research & development. It’s clear that the company can work with clients right through the drug discovery process, from target identification through to lead identification, compound optimisation and onwards to scale-up. Time is saved and value added by cutting out inefficiencies along the way, ensuring that clients’ compounds are in the best possible position for future market success.

CEO of Charnwood Molecular, Steve Allin, commented: "The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories provide substantial capacity for future growth and expansion of our current scientific teams, along with the future addition of related drug discovery service lines."